pentobarbital will decrease the level or influence of linagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Use of different therapies is strongly proposed when linagliptin should be to be administered with a CYP3A4 inducerpentobarbital will minimize the extent or influence of estropipate by impacting hepa